Autonomix Medical Receives Nasdaq Minimum Bid Price Notice

Autonomix Medical, Inc. ( (AMIX) ) has provided an update.

On January 14, 2026, Autonomix Medical, Inc. disclosed that it received a deficiency letter from Nasdaq after its common stock traded below the $1.00 minimum bid price for 30 consecutive business days, putting the company out of compliance with Nasdaq’s continued listing requirements. The notice does not trigger an immediate delisting, and Autonomix now has until July 13, 2026, to regain compliance by achieving a closing bid price of at least $1.00 for a minimum of 10 consecutive business days, with the potential for an additional 180-day grace period, a development that introduces uncertainty for shareholders while providing the company time to stabilize its share price and maintain its Nasdaq listing.

The most recent analyst rating on (AMIX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Autonomix Medical, Inc. stock, see the AMIX Stock Forecast page.

Spark’s Take on AMIX Stock

According to Spark, TipRanks’ AI Analyst, AMIX is a Underperform.

Autonomix Medical, Inc. struggles with severe financial performance issues due to zero revenue and negative cash flow, despite low debt levels. Technical analysis suggests some short-term momentum, but a longer-term downtrend persists. Valuation is significantly impacted by negative earnings and no dividend yield. Positive trial outcomes present a potential opportunity but are insufficient to offset the substantial financial challenges.

To see Spark’s full report on AMIX stock, click here.

More about Autonomix Medical, Inc.

Autonomix Medical, Inc. is a medical company whose common stock is listed on the Nasdaq Capital Market, giving it access to public equity capital and visibility among healthcare and medtech investors.

Average Trading Volume: 8,388,005

Technical Sentiment Signal: Sell

Current Market Cap: $3.66M

Find detailed analytics on AMIX stock on TipRanks’ Stock Analysis page.